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Bcl-2 regulates activation of apoptotic proteases in a 
cell-free system
Sabina C. Cosulich*, Stephen Green† and Paul R. Clarke*
Background: Apoptosis plays an important role in the normal development and
homeostasis of metazoans. Aberrations in this process have been implicated in
several major human diseases, but its molecular mechanism is poorly
understood. In animals as diverse as humans and nematodes, the Bcl-2
oncoprotein prevents or delays apoptosis, whereas proteases of the
interleukin-1b-converting enzyme (ICE) family are required, suggesting that they
are components of a conserved mechanism controlling the onset of apoptosis.
Results: A cell-free system produced from Xenopus laevis eggs reproduces
nuclear events characteristic of apoptosis after a lag phase. We have used this
system to define the temporal sequence of biochemical events and to examine
the relationship between Bcl-2 and apoptotic proteases. Bcl-2 prevents
apoptotic chromatin condensation and DNA cleavage, but only when added prior
to the activation of a protease which has characteristics similar to the Ced-3
sub-family of ICE-like proteases and which cleaves poly(ADP-ribose) polymerase
(PARP). Bcl-2 attenuates activation of this protease, an effect that does not
require de novo protein synthesis or the presence of intact nuclei. The
Ced-3-related protease CPP-32 is cleaved during the late stages of apoptosis in
this system and after PARP cleavage. Generation of CPP-32-cleaving activity is
inhibited by Bcl-2. 
Conclusions: These experiments provide direct biochemical evidence that Bcl-2
protects against apoptosis, at least in part, by regulating the activation of a series
of apoptotic proteases that cleave PARP and other substrates. This cell-free
system provides a useful biochemical model for analyzing the molecular
mechanism controlling the activation of these proteases.
Background
Apoptosis, a form of cell death, has been proposed to play
an important role in normal morphogenesis, tissue re-
modelling and the establishment of immune self-tolerance
[1]. It is also the method of cell killing mediated by cyto-
toxic T lymphocytes, and is induced by g or ultraviolet
irradiation, viral infection, or exposure to a variety of cyto-
toxic drugs. Inappropriate apoptosis has been proposed to
underlie many human degenerative diseases, whereas
resistance to apoptosis may contribute to viral infection
and neoplastic transformation [2,3].
Although a wide variety of stimuli can induce apoptosis,
most cells undergoing the process exhibit a similar series of
changes, suggesting a common biochemical mechanism.
Following a stimulus that triggers the process, there is a
latent phase during which no apparent changes are observed
but the cells become committed to die. This period is often
variable in length within a population of cells and may
involve changes in gene expression. Subsequently, the cells
undergo dramatic morphological changes that include
plasma-membrane blebbing, chromatin condensation and
nuclear fragmentation. In many cases, genomic DNA is
severed into oligonucleosomal fragments that produce a
characteristic ladder when separated on agarose gels. 
The Bcl-2 oncoprotein delays or prevents apoptosis trig-
gered by a variety of stimuli, indicating that it controls a
common process [4,5]. Genetic studies on the nematode
Caenorhabditis elegans have identified a homologous gene,
ced-9, which acts to suppress cell death during development
[6,7]. Importantly, human Bcl-2 is able to suppress apoptosis
in ced-9 mutants [7,8], demonstrating the conserved nature
of the mechanism modulated by Bcl-2. Bcl-2 is one of a
family of related proteins found in mammalian cells, some
of which function as death suppressors and others which
promote apoptosis [4,5]. These proteins have been pro-
posed to function by forming homodimers and heterodimers
[9], but the mechanism of their action is unknown.
In contrast to ced-9, other genes are required in order for
apoptosis to occur in C. elegans [10]. Deletion or mutation
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of the ced-3 gene completely blocks developmental cell
death [11]. The ced-3 gene [12] encodes a cysteine pro-
tease related to interleukin-1b (IL-1b)-converting enzyme
(ICE), which cleaves pro-IL-1b at a specific aspartate
residue [13,14]. Although ICE itself can induce apoptosis
when overexpressed in mammalian cells [15], mice geneti-
cally deficient in ICE develop normally and, in most
cases, cells from these animals are capable of undergoing
apoptosis [16,17]. However, a number of additional ICE-
related proteases are present in mammalian cells which
may play more central roles in apoptosis [18,19]. 
An early event during the apoptosis of many mammalian
cells is the cleavage of poly(ADP-ribose) polymerase
(PARP) from its active 116 kDa form to an 89 kDa frag-
ment [20–23]. The role of PARP in apoptosis is still not
clear, but cleavage may inhibit DNA-repair processes [20].
Lazebnik et al. [21] showed that human PARP was
cleaved at the site DEVD↓G (single-letter amino-acid
code) which separates the DNA-binding domain from the
catalytic domain. The protease activity responsible, which
they called prICE, resembles ICE in its susceptibility to
chemical inhibitors, but is distinct, because purified ICE
did not cleave PARP efficiently. A PARP-cleaving pro-
tease, also referred to as apopain [22] or Yama [23], has
been identified recently as the product of the human CPP-
32 gene [24]. Nicholson et al. [22] demonstrated that a
potent inhibitor of CPP-32 derived from the cleavage site
in PARP inhibits nuclear morphological changes and
DNA cleavage as well as PARP cleavage in mammalian
apoptotic cell lysates. Furthermore, the inhibitor blocks
camptothecin-induced apoptosis of osteosarcoma cells.
These results suggest that CPP-32 or a similar protease
plays a key role in mammalian apoptosis. CPP-32 is one of
a subfamily of ICE-related proteases more similar to Ced-
3 than ICE. Other members of this subfamily that have
been identified recently include Mch-2 [25] and
Mch-3/ICE-LAP3 [26,27]. Perhaps significantly, CPP-32,
Ced-3 and Mch-3 all cleave PARP in vitro [22,26,28], sug-
gesting that they have similar substrate specificities. It is
not yet clear, however, whether these proteases are func-
tional homologues of Ced-3 or have distinct roles. Like
other members of the ICE family, they are synthesised as
precursors that are activated by cleavage at specific aspar-
tate residues [18], but the control of their processing and
activation is unknown. One possibility is that they are acti-
vated sequentially, forming a proteolytic cascade.
A critical issue in understanding the molecular mechanism
of apoptosis is to define the biochemical pathway leading
to DNA cleavage and the roles of the Bcl-2 family and the
apoptotic proteases. Recent experiments using cultured
mammalian cells have have suggested that Bcl-2 works
upstream of CPP-32 and Mch-3/ICE-LAP3 [29,30], in
agreement with genetic studies in C. elegans which indi-
cated that Ced-9 acts upstream of Ced-3 [10]. However,
the temporal sequence of events during the onset of apop-
tosis and the relationship between Bcl-2 and apoptotic
proteases remains to be determined. To address this
problem, we have used a cell-free system, produced from
Xenopus laevis eggs, which undergoes apoptotic chromatin
condensation and DNA fragmentation synchronously after
a lag period. Bcl-2 can inhibit the apoptotic process when
added early in the lag period [31]. Concentrated extracts
of Xenopus eggs maintain the intracellular balance of
protein concentrations and enzyme activities, and have
been shown to faithfully reproduce complex processes of
the cell cycle and their control (for example, [32,33]). We
find that apoptosis in this system requires the activity of
proteases that have characteristics of the Ced-3 sub-family
of ICE-related proteases. A protease that cleaves PARP is
activated prior to chromatin condensation and DNA cleav-
age. Bcl-2 only functions before the activation of this pro-
tease and attenuates its activation. The cleavage of
CPP-32 precursor is inhibited indirectly by Bcl-2,
although the CPP-32 precursor-cleaving activity is gener-
ated late in apoptosis in this system. These results provide
direct biochemical evidence that Bcl-2 can prevent or
delay apoptosis by modulation of a temporal series of
apoptotic proteases.
Results
Isolated HeLa cell nuclei added to concentrated Xenopus
egg extracts arrested in interphase were found to be stable
for up to 3 hours of incubation. In the majority of prepara-
tions, the extracts then exhibited apoptotic DNA cleavage
observed as the appearance of polynucleosomal DNA frag-
ments on agarose gels (Fig. 1a). These changes were
accompanied by chromatin condensation typical of apop-
totic cells (Fig. 2b). As found previously by Newmeyer et
al. [31], the addition of Bcl-2 (produced in Sf21 insect
cells) at the start of the incubation completely inhibited
subsequent DNA cleavage (Fig. 1b) and morphological
changes (Fig. 2c). Control Sf21 cell lysates immunode-
pleted of Bcl-2 or prepared from cells producing unrelated
proteins (CDK4/cyclin D1) had no effect. These extracts
therefore provide a useful cell-free system to study the
mechanism of action of the Bcl-2 family. Protein synthesis
was inhibited in the extracts by the presence of cyclohexa-
mide, so the inhibitory effect of Bcl-2 was entirely post-
translational. Furthermore, the extracts were arrested in
interphase and contained little or no mitotic cyclins,
excluding a role for mitotic cyclin-dependent protein
kinases in this process. Bcl-2 functions only during the
early part of the lag period, well before any nuclear
changes are apparent [31]; the addition of Bcl-2 after
1.5 hours of incubation of the nuclei in the extract did not
prevent subsequent apoptotic events and the appearance
of DNA cleavage fragments when assayed 4 hours after
the start of the experiment (Fig. 3a), although Bcl-2 was
stable in the extracts throughout the time course of
incubation (data not shown).
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To investigate the possible role of ICE-like proteases in
the apoptotic process in this system, we used tetrapeptide
aldehyde inhibitors based upon the sites of cleavage in
substrate proteins. Ac-DEVD-CHO, a potent inhibitor of
human CPP-32 protease (Ki CPP-32 < 1 nM; [22]) and
probably other closely related proteases, is derived from
the cleavage site in the substrate PARP [21]. When added
at the start of the incubation, Ac-DEVD-CHO completely
abolished DNA fragmentation at concentrations as low as
1 nM (Fig. 1c). Ac-DEVD-CHO also prevented the
nuclear morphological changes associated with apoptosis
(Fig. 2d). In contrast, Ac-YVAD-CHO, another tetra-
peptide aldehyde which potently inhibits ICE
(Ki ICE = 0.76 nM; Ki CPP-32 = 12 mM [22]), only inhib-
ited DNA cleavage (Fig. 1c) and chromatin condensation
(Fig. 2e) when added at 10 mM, in agreement with studies
using other cell-free systems and similar inhibitors derived
from the cleavage site of interleukin-1b [21,22,34,35]. The
cysteine protease inhibitor E64 and the serine protease
inhibitor TPCK had no effect, even at very high concen-
trations (Fig. 1c). These results are consistent with the
requirement for a protease activity with similar character-
istics to the Ced-3 sub-family of ICE-related proteases for
nuclear events of apoptosis in Xenopus egg extracts, as
reported recently for human and chicken cell extracts [22].
Addition of Ac-DEVD-CHO at different times during the
incubation of the extracts determined that protease activ-
ity was required up to 2.5 hours of incubation for subse-
quent DNA cleavage to occur (Fig. 3b), considerably later
than the point at which Bcl-2 ceased to function. This
shows that Bcl-2 functions prior to Ac-DEVD-CHO-sensi-
tive proteases in the temporal sequence of events during
the onset of apoptosis. 
The cleavage site in human PARP [21] is conserved in
Xenopus PARP [36], suggesting that Xenopus PARP may be a
substrate for apoptotic protease activity in the egg extracts.
To examine PARP-cleaving activity directly, we produced
Xenopus PARP using an in vitro transcription/translation
system. When added to the extracts, PARP was stable for
up to 1 hour, after which time it was efficiently cleaved to
produce a polypeptide similar in size to the 85 kDa frag-
ment of human PARP produced by CPP-32 activity (Fig.
4a) [20–23]. This proteolysis was completely inhibited by
Ac-DEVD-CHO added at the start of the incubation (Fig.
4c). The addition of Bcl-2 in Sf21 cell lysates delayed
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Figure 1
DNA degradation in Xenopus egg extracts is inhibited by Bcl-2 and
tetrapeptide aldehyde inhibitors. (a) Time course of DNA cleavage in
HeLa nuclei during incubation in Xenopus egg extracts at 23 °C.
Samples were removed at the times shown and analysed by agarose gel
electrophoresis. The sizes (in base pairs) of the DNA markers (M) are
indicated on the right. (b) Inhibition of DNA cleavage by Bcl-2 protein.
Sf21 cell lysates containing Bcl-2 were added to the extract at the start
of the incubation, at 1/100 dilution. DNA cleavage was analyzed at the
times indicated. (c) Inhibition of DNA cleavage by tetrapeptide aldehyde
inhibitors added at the start of incubations. Protease inhibitors were
added at the start of the incubation and DNA cleavage was assayed 4 h
later. Ac-DEVD-CHO and Ac-YVAD-CHO were added at the
concentrations shown; E64 and TPCK were at 100 mM.
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PARP cleavage, with significant cleavage only occurring
after 4 hours (Fig. 4b). The cleavage of Xenopus PARP and
its attenuation by Bcl-2 were not dependent on the pres-
ence of nuclei in the extracts, although when Hela nuclei
were added, the human PARP contained in the nuclei was
cleaved with very similar kinetics (data not shown).
These results suggested that Bcl-2 was inhibiting or delay-
ing the appearance of a Xenopus apoptotic PARP protease
activity, which we will refer to as XAPP. For a more quanti-
tative assay of XAPP, we used a tetrapeptide derivative
based upon the site of proteolysis in PARP, which under-
goes a change in fluorescence when cleaved (Z-DEVD-
AFC). XAPP was initially inactive in the extract, but was
activated to a high level within 1 hour (Fig. 5a). In contrast,
no activity towards an ICE substrate (DABCYL-YVADAP-
EDANS; [37]) was observed (data not shown). This activa-
tion of XAPP was partially blocked by the prior addition of
lysates of Sf21 cells expressing Bcl-2. When Bcl-2 protein
was immunoprecipitated from these lysates, inhibition of
XAPP activation was not observed (Fig. 5a), whereas a
mock depletion had no effect on their ability to prevent
XAPP activation (data not shown). It is possible, however,
that additional factors in the lysates were specifically co-
depleted with Bcl-2. Lysates from Sf21 cells infected with
unrelated proteins (CDK4 and cyclin D1) did not inhibit
the activation of XAPP (Fig. 5a). The addition of lysates
containing Bcl-2 3 hours after the start of the incubation
had no effect on XAPP activity (although Ac-DEVD-CHO
still inhibited XAPP efficiently at this time; Fig. 5b),
excluding the possibility that a direct inhibitor of XAPP,
such as baculovirus p35 protein [28,38] which might be
present in the Sf21 cell lysates, was responsible. Together,
these data suggest that Bcl-2 functions upstream in the
apoptotic pathway to regulate the activation of XAPP,
rather than simply as an inhibitor of XAPP. 
In order to investigate the regulation by Bcl-2 of protease
activation, and the relationship between XAPP and
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Figure 3
Addition of Bcl-2 or Ac-DEVD-CHO to Xenopus egg extracts during a
time course of incubation. (a) Bcl-2 or (b) Ac-DEVD-CHO was added
to the extracts during the incubations at the times indicated. For all
samples, DNA cleavage was assayed by agarose gel electrophoresis
4 h after the start of the incubation.
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Figure 2
Inhibition of nuclear morphological changes in Xenopus egg extracts by
Bcl-2 and tetrapeptide aldehyde inhibitors. HeLa nuclei were incubated
in Xenopus egg extracts in the presence of (a,b) control buffer, (c)
Sf21 cell lysates containing Bcl-2, (d) 10 nM Ac-DEVD-CHO or 
(e) 10 mM Ac-YVAD-CHO. Samples were removed after (a) 1 h or
(b–e) 4 h, stained for chromatin using Hoechst 33342 and examined
by fluorescence microscopy. 
CPP-32 (recently suggested to play a central role in the
control of apoptosis in mammalian cells [22,23]), we
produced the inactive 32 kDa precursor of human CPP-32
[24] in vitro. Formation of the active enzyme requires pro-
teolytic cleavage to produce the two fragments of approxi-
mately 20 and 11 kDa found in cells undergoing apoptosis
[22,23,39]. When added to the extracts at the start of incu-
bation, the 32 kDa precursor was initially stable, but was
later cleaved to the active fragments, indicating that
CPP-32 precursor-cleaving activity was generated during
the latent phase (Fig. 6). However, this CPP-32 precursor-
cleaving activity was not present until 3–3.5 hours after
the start of the incubation (Fig. 6a), about 1.5 hours later
than the time of PARP cleavage (Fig. 4a). Prior addition of
Bcl-2 completely inhibited CPP-32 precursor cleavage
(Fig. 6b), but Bcl-2 protein was only able to block the
cleavage when added during the initial 1.5 hours of extract
incubation (Fig. 6c), the period during which it also func-
tions to prevent subsequent DNA cleavage. This result
suggested that Bcl-2 was inhibiting the generation of a
CPP-32 precursor-cleaving activity rather than having a
direct effect on the cleavage of CPP-32. We examined this
further by adding Bcl-2 to extracts incubated to generate
CPP-32 precursor-cleaving activity before CPP-32 precur-
sor was added. Bcl-2 had no effect under these conditions,
whereas Ac-DEVD-CHO, but not Ac-YVAD-CHO, com-
pletely blocked CPP-32 precursor cleavage (Fig. 6d).
Research Paper  Regulation of apoptotic proteases by Bcl-2 Cosulich et al. 1001
Figure 4
Bcl-2 delays the cleavage of PARP in Xenopus egg extracts. Xenopus
[35S]-PARP was generated by in vitro transcription/translation and
added to the extracts at the start of the incubation. (a) Control Sf21
lysate, (b) Bcl-2 protein in Sf21 lysate or (c) Ac-DEVD-CHO (10 nM)
was added at the start of the incubation, as described in Fig.1.
Samples were removed for analysis by polyacrylamide gel
electrophoresis and autoradiography at the times shown. The positions
of molecular mass marker proteins (Biorad) are indicated on the right
and are approximate values (in kDa) only.
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Figure 5
Bcl-2 attenuates activation of apoptotic protease (XAPP) activity in
Xenopus egg extracts. (a) Bcl-2 in Sf21 cell lysates or the tetrapeptide
aldehyde Ac-DEVD-CHO were added to the extracts at the start of the
incubation. At the times indicated, aliquots were removed, diluted and
incubated with 50 mM fluorogenic substrate Z-DEVD-AFC for 10 min
before measuring fluorescence. Lysates from Sf21 cells either
non-infected, expressing Bcl-2 but immunodepleted of Bcl-2 protein, or
expressing unrelated proteins (CDK4 and cyclin D1) were used as
controls. (b) Addition of Bcl-2 in cell lysates 3 h after the start of the
incubation does not affect XAPP activity. Addition of lysates from Sf21
cells expressing Bcl-2 or unrelated proteins (CDK4 and cyclin D1) 3 h
after the start of the incubation did not affect the cleavage of the
fluorogenic substrate Z-DEVD-AFC. In contrast, addition of 100 nM
Ac-DEVD-CHO to the extract 3 h after the start of the incubation
completely abolished cleavage of Z-DEVD-AFC.
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Discussion
Using a cell-free system of Xenopus egg extracts, we have
begun to define the temporal sequence of events during
the apoptotic process that results in nuclear chromatin con-
densation and DNA cleavage (Fig. 7). Although Xenopus
eggs do not normally undergo apoptosis even in the
absence of the survival signals required by most cells [1], it
is evident that the molecular components required for the
process pre-exist in egg extracts. Nuclei added to the
extracts are stable for several hours of incubation before
undergoing changes typical of apoptosis. During this lag
period, however, biochemical changes are occurring. We
find that a protease activity that cleaves PARP is dramati-
cally activated within 1 hour of incubation. This Xenopus
apoptotic PARP protease activity, which we have called
XAPP, is similar to Ced-3-related apoptotic proteases in its
inhibitor sensitivity and its apparent substrate specificity,
suggesting that such proteases are a universal component
of the apoptotic mechanism. Interestingly, the precursor of
a human Ced-3-related protease, CPP-32, when added to
the extracts is cleaved to its active form late in the apop-
totic process at about the same time as DNA cleavage
occurs. Indeed, generation of a CPP-32 precursor-cleaving
activity occurs after PARP cleavage is complete.
Although we do not know what initiates the apoptotic
process in these extracts, a control point regulated by the
Bcl-2 oncoprotein is present. We find that Bcl-2 is func-
tional only during a period prior to the activation of XAPP.
Indeed, Bcl-2 added to the extracts early in the lag phase
attenuates the activation of XAPP. However, there is sig-
nificant XAPP activation after prolonged incubation in the
presence of Bcl-2. One possibility is that only a compo-
nent of total XAPP activity is essential for apoptosis and
that its activation is blocked efficiently by Bcl-2. This
component might reflect a different gene product or a
compartmentalized fraction. If XAPP is an ICE-related
protease, its activation may be due to proteolytic cleavage.
However, determination of the precise relationship of
XAPP to other apoptotic proteases and its mechanism of
activation will require molecular cloning.
Cleavage of human CPP-32 in the extracts is also blocked
by early addition of Bcl-2. Importantly, Bcl-2 does not
inhibit CPP-32 cleavage directly, and CPP-32-cleaving
activity is generated 1.5 hours after Bcl-2 ceases to be effec-
tive. CPP-32 cleavage is inhibited by Ac-DEVD-CHO,
indicating that this proteolytic activity may be due to a
related enzyme. As there is a significant temporal gap
between the initial activation of PARP-cleaving activity
and the appearance of CPP-32-cleaving activity, there are
probably at least two distinct proteases, possibly more,
being activated in a temporal sequence. It remains to be
determined whether XAPP activation is part of cascade
leading to CPP-32 cleavage or a collateral event. A number
of human proteases closely related to CPP-32 and Ced-3
have been identified; these may be part of an apoptotic
cascade, but their individual roles are unknown at present.
The mechanism by which Bcl-2 controls activation of
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Figure 6
Cleavage of CPP-32 is inhibited indirectly by Bcl-2. (a,b) Time course
of CPP-32 cleavage in Xenopus egg extracts. Human [35S]-CPP32
was generated by in vitro transcription/translation and added at the
start of the incubation to the extracts (a) without or (b) with Bcl-2 in
Sf21 cell extracts added at time 0. Samples were removed at the times
shown and analyzed by polyacrylamide gel electrophoresis and
autoradiography. The positions of molecular mass marker proteins
(Biorad) are indicated on the right and are approximate values (in kDa)
only. In (c), incubations were performed with [35S]-CPP32 for 4 h, but
Bcl-2 was added to the extracts at the times indicated. In (d), Bcl-2,
Ac-DEVD-CHO (100 nM) or Ac-YVAD-CHO (100 nM) were added to
the extracts after 4 h incubation, just prior to addition of [35S]-CPP32. 
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apoptotic proteases remains unclear, but presumably Bcl-2
inhibits one of the initial events in the process, functioning
at, or upstream of, the activation of XAPP. Importantly,
this study establishes that control of apoptotic proteases by
Bcl-2 does not require de novo protein synthesis and occurs
in the absence of intact nuclei.
The decision to activate apoptotic proteases is critical in
determining the survival of cells and is likely to be subject
to tight controls. Other members of the Bcl-2 family,
including pro-apoptotic proteins such as Bak and Bax, may
act at the same cytoplasmic control point as Bcl-2.
Changes in the expression of Bcl-2 family proteins or their
activities, particularly the balance between pro- and anti-
apoptotic regulators may regulate the initiation of the
apoptotic protease cascade. Changes in the expression of
the death proteases themselves may also alter the predis-
position of a cell to apoptosis, but their activation would
still be modulated by Bcl-2 family proteins. This may
explain the ability of Bcl-2 to protect cells against apopto-
sis triggered by the overexpression of ICE-related
proteases in their precursor form [15]. To bypass the Bcl-2
control point, extracellularly mediated signals may
activate the apoptotic proteases downstream of Bcl-2
directly, for instance by the introduction of an active
protease such as granzyme B [39], which occurs during
cytotoxic T-cell mediated cell killing, or signals, as yet
uncharacterized, from the Fas/Apo-1 receptor [37,40–43].
Although this study shows that Bcl-2 cannot block apopto-
sis after PARP-cleaving proteases have been activated, the
pathway may be negatively regulated at other points by
additional mechanisms. Viral proteins such as the cowpox
virus serpin crmA [23] and p35 from baculovirus [28,38]
are able to inactivate apoptotic proteases directly,
although it is not clear whether cellular homologues of
these proteins exist. In addition to temporal regulation of
the pathway, there may be a spatial regulation due to the
subcellular distribution of components.
The downstream substrates of apoptotic proteases remain
to be fully characterized. In this system, PARP cleavage
occurs 2–3 hours before DNA fragmentation and may con-
tribute to the process. However, inhibition of apoptotic
proteases with Ac-DEVD-CHO after PARP cleavage has
occurred still completely blocks DNA fragmentation.
PARP cleavage is not sufficient for DNA fragmentation,
therefore, suggesting that the proteolysis of other sub-
strates is required after PARP cleavage. Some of these
reactions may be catalyzed by the same enzymes that
cleave PARP or by other proteases activated as part of a
cascade. It is possible that CPP-32 plays an important role
at this stage of the process. Additional nuclear proteins
that have been identified as potential substrates for apop-
totic proteases include lamins [44,45], topoisomerase 1
[46], the 70 kDa component of the U1 small nuclear
ribonucleoprotein [47], protein kinase Cd [48] and
PITSLRE protein kinase [49]. The cleavage of a number
of proteins may be required for the final coup de grace of
DNA cleavage to be initiated [19], although some sub-
strates, rather than acting directly to bring about changes
in nuclear morphology and chromatin structure, may be
involved in switching off recovery processes such as DNA
repair. Cleavage of other substrates may be inconsequen-
tial. To determine the roles of the targets of this apoptotic
cascade, as well as the mechanism of its initiation, will
require a thorough dissection of the function of each
protein. This will be greatly facilitated by the use of cell-
free systems such as the one used here.
Conclusions
The results of this study, together with genetic information
from C. elegans and experiments using cultured mammalian
cells, establish that the molecular mechanism of apoptosis
involves the activation of a series of proteases that cleave
specific substrates. The initiation of these essentially irre-
versible reactions that lead to cell death must be tightly
controlled. Bcl-2 inhibits activation of the proteases, and
this may account for its ability to delay or prevent
apoptosis. Understanding precisely how Bcl-2 regulates the
activation of apoptotic proteases may shed further light on
the mechanism controlling the initiation of apoptosis and
how it may be manipulated pharmacologically.
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Figure 7
Temporal regulation of events during apoptosis in Xenopus egg
extracts. Bcl-2 is functional only during the period prior to XAPP
activation. In the absence of Bcl-2, PARP is cleaved after 2 h
incubation, but apoptotic protease activity inhibitable by
Ac-DEVD-CHO is still required for subsequent nuclear changes at
2.5 h. At about this time, CPP-32 cleavage, chromatin condensation
and DNA cleavage are initiated. 
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Materials and methods
Preparation of Xenopus egg extracts and HeLa nuclei.
Xenopus egg extracts were prepared at 4 °C as 10 000 g supernatants
supplemented with an ATP-regenerating system, cytochalasin B, cyclo-
hexamide and 5 % (v/v) glycerol [32,33]. They were snap-frozen in
100 ml aliquots and stored in liquid nitrogen. Incubations were initiated
immediately after thawing the extracts at 23 °C. Most extracts prepared
in this way become apoptotic after 3–5 h of incubation, although some
are stable for up to 12 h. However, aliquots of a particular extract showed
highly reproducible kinetics. Extracts used in the experiments shown
were matched for the timing of DNA fragmentation. We have found no
evidence that variation in the period between the priming of oocyte
growth and induction of ovulation [31] influences the state of the extract. 
HeLa nuclei were prepared essentially as described by Wood and
Earnshaw [50] and maintained at –80 °C in storage buffer (10 mM
PIPES, 80 mM KCl, 20 mM NaCl, 250 mM sucrose, 5 mM EGTA,
1 mM DTT, 0.5 mM spermidine, 0.2 mM spermine, 1 mg ml–1 protease
inhibitors, 50 %(v/v) glycerol). Immediately after thawing, the nuclei
were washed at 4 °C in nuclear buffer (10 mM PIPES, 10 mM KCl,
2 mM MgCl2, 1 mM DTT, 10 mM cytochalasin B, 1 mg ml–1 aprotinin,
1 mg ml–1 leupeptin, 1 mg ml–1 pepstatin, 1 mg ml–1 chymostatin,
1 mg ml–1 antipain) and added to extracts at the start of incubation in
1/10 volume to give a final concentration of 1000 per ml. 
Agarose gel electrophoresis and SDS–PAGE analysis
During the incubation of extracts (typically 100 ml) at 23 °C, samples
were removed for analysis of DNA or proteins. Samples for DNA analy-
sis were prepared as follows: 10 ml aliquots of extract were taken at
the times indicated, added to 90 ml lysis buffer (10 mM Tris pH 8.0,
100 mM EDTA, 0.5 % SDS, 200 mg ml–1 proteinase K) and incubated
overnight at 52 °C. Samples were then phenol-extracted, ethanol-pre-
cipitated and run on 1 % agarose gels. Gels were then incubated in
Tris-borate EDTA buffer containing 0.5 mg ml–1 ethidium bromide and
300 mg ml–1 RNase for 2 h. For analysis of proteins: 5 ml aliquots of
extract were added to 10 ml SDS–PAGE gel sample buffer for
SDS–PAGE. Gels were transferred to nitrocellulose for western
immunoblotting or dried for autoradiography.
Microscopy
Aliquots (1 ml) of extract were removed from incubations and mixed
with 4 ml fix buffer (10 % (v/v) formaldehyde, 50 % (v/v) glycerol,
100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 0.1 mM EDTA, 1 mg ml–1
Hoechst 33342, 5 mM HEPES, pH 7.8). Fluorescence microscopy
was performed using a Zeiss Axiophot microscope.
Bcl-2 cloning and expression
A full length Bcl-2 cDNA was subcloned into the pVL1393 baculovirus
vector (Invitrogen). Bcl-2 was expressed in Sf21 insect cells. Expres-
sion was confirmed by western immunoblotting (anti-Bcl-2 monoclonal
antibody, Dako). Cell lysates containing Bcl-2 were prepared as
described by Newmeyer et al. [31] and were added at 1/100 dilution
to the extracts. This gave a final concentration comparable to that in
transfected MuTu Burkitt’s lymphoma cells, as determined by antibody
detection. Immunodepletion experiments were carried out using the
same antibody and protein A agarose beads.
Inhibitors and substrates of ICE family proteases 
Tetrapeptide aldehydes Ac-DEVD-CHO and Ac-YVAD-CHO (SNPE
Ltd, Strasbourg) were dissolved in 100 mM Hepes, pH 7.4 and added to
the extracts at the concentrations shown. The fluorogenic tetrapeptide-
aminofluorylcoumarin Z-DEVD-AFC (Enzyme Systems Products) was
dissolved at 5 mM in dimethyl formamide and then diluted to 500 mM in
100 mM Hepes, pH 7.4. Aliquots (9 ml) of Xenopus egg extract were
taken at the times indicated, 1 ml of diluted Z-DEVD-AFC was added to
give a final concentration of 50 mM and the cleavage reaction was
carried out at 23 °C. Samples were then diluted to 2 ml in phosphate-
buffered saline which abolished any further Z-DEVD-AFC cleaving
activity. Free AFC was detected using a fluorimeter using an excitation
wavelength of 400 nm and an emission wavelength of 505 nm. The
reaction was linear with respect to time for at least 20 min in extracts
that had been preincubated to give maximal protease activity. Values
shown were measured after a reaction time of 10 min. 
In vitro transcription/translation
The Xenopus PARP clone pBS-XLPARP (a generous gift from B.
Saulier-Le Drean and M. Philippe) was expressed using a coupled in
vitro transcription/translation system (Promega) with T3 polymerase
and labelled with [35S]-methionine (1000 Ci mmol–1) prior to incubation
in the extracts. CPP-32 was cloned from HT1376 bladder cells by
reverse transcriptase–PCR and subcloned into the pcDNA3 vector for
expression using the coupled in vitro transcription/translation system
described above with T7 polymerase.
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